Diagnosis and management of benign prostatic hyperplasia in primary care

Journal of the Canadian Urological Association

Volumn 3, Issue 3 SUPPL. 2, 2009, Pages

  Tanguay, Simon ^a   Awde, Murray ^b   Brock, Gerald ^b   Casey, Richard ^c   Kozak, Joseph ^d   Lee, Jay ^e   Nickel, J Curtis ^f   Saad, Fred ^g  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Male Health Centres   (United States)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69249141261     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Nickel JC. The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Curr Opin Urol 2006; 16: 5-10.
2. IMS Canadian Disease and Therapeutic Index. Q4 (Dec. MAT). 2004.
3. Naslund MJ, Costa FJ, Miner MM. Managing enlarged prostate in primary care. Int J Clin Pract 2006; 60: 1609-15.
4. Miner M. Primary care physician vs urologist: How does their medical management of LUTS due to BPH differ? Weill Medical College of Cornell University Reports on Men's Urologic Health 2[1]. http://www.cornellurology.com/ publications/mens-urologic-health-2-1.pdf. Accessed November 3, 2008.
5. Nickel JC, Herschorn S, Corcos J, et al; Canadian Prostate Health Council; Canadian Urological Association Guidelines Committee. Canadian guidelines for the management of benign prostatic hyperplasia. Can J Urol 2005; 12: 2677-83.
6. American Urological Association. The American Urological Association (AUA) Symptom Index for Benign Prostatic Hyperplasia (BPH) and the Disease Specific Quality of Life Question. http://www.auanet.org/content/guidelines-and- quality-care/clinical-guidelines/main-reports/bph-management/chapt-1-appendix. pdf. Accessed October 15, 2008.
7. Wei JT, Nuckolls J, Miner M. Differences in medical management of LUTS/BPH between PCPs and urologists. Abstract 7, American Urological Association 2006 Conference; May 20-25, 2006; Atlanta, GA.
8. Kirby RS, Chisholm G, Chapple C, et al. Shared care between general practitioners and urologists in the management of benign prostatic hyperplasia: a survey of attitudes among clinicians. J R Soc Med 1995; 88: 284P-288P.
9. Edwards JL. Diagnosis and management of benign prostatic hyperplasia. Am Fam Physician 2008; 77: 1403-10.
10. Neal DE, Neal RR, Donovan J. Benign Prostatic Hyperplasia. In: Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews. Edited by Stevens A, Raftery J, Mant J, Simpson S. Abington: Radcliffe Publishing, chapt. 12, 2004: 91-158.
11. Konwar R, Chattopadhyay N, Bid HK. Genetic polymorphism and pathogenesis of benign prostatic hyperplasia. BJU Int 2008 Aug. 5; 102: 536-44.
12. Rosenberg MT, Staskin DR, Kaplan SA, et al. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 2007; 61: 1535-46.
13. AUA Practice Guideline Committee. AUA guideline on management of benign prostatic hyperplasia (2003). http://www.auanet.org/content/guidelines-and- quality-care/clinical-guidelines.cfm?sub=bph. Accessed October 16, 2008.
14. Levy A, Samraj GP. Benign prostatic hyperplasia: when to 'watch and wait,' when and how to treat. Cleve Clin J Med 2007; 74 (Suppl 3): S15-20.
15. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, CombAT, and ALF-ONE. BJU Int 2008; 101 (Suppl 3): 17-21.
16. Davidson JH, Chutka DS. Benign prostatic hyperplasia: treat or wait? J Fam Pract 2008; 57: 454-63.
17. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002; 59: 245-50.
18. DeCastro J, Stone B. Improving therapeutic outcomes in BPH through diagnosis, treatment and patient compliance. Am J Med 2008; 121 (8 Suppl 2): S27-33.
19. Barkin J. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm. Can J Urol 2008; 15 (Suppl 1): 21-30.
20. Canadian Prostate Cancer Network. International Prostate Symptom Score (IPSS). http://www.cpcn.org/ipss.pdf. Accessed October 15, 2008.
21. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6, 630 men. J Urol 1994; 151: 1283-90.
22. LaSpina M, Haas GP. Update on the diagnosis and management of prostate cancer. Can J Urol 2008; 15 (Suppl 1): 3-13.
23. Levitt JM, Slawin KM. Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression. Curr Urol Rep 2007; 8: 269-74.
24. Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163: 13-20.
25. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection V.2.2007. http://www.nccn.org/ professionals/physician-gls/PDF/prostate-detection.pdf. Accessed October 15, 2008.
26. Emberton M, Zinner N, Michel MC, et al. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. BJU Int 2007; 100: 249-53.
27. Djavan B, Chapple C, Milani S, et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64: 1081-8.
28. Gittens PR, Lallas CD, Pe ML, et al. Uropharmacology for the primary care physician. Can J Urol 2008; 15 (Suppl 1): 78-91.
29. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006; 97 (Suppl 2): 34-8.
30. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179-84.
31. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-63.
32. McConnell JD, Roehrborn CG, Bautista OM, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98.
33. Debruyne F, Barkin J, van Erps P, et al; ARIA3001, ARIA3002 and ARIB3003 Study Investigators. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46: 488-94.
34. Roehrborn CG, Boyle P, Nickel JC, et al; ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41.
35. Roehrborn CG, Siami P, Barkin J, et al; CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616-21.
36. Musquera M, Fleshner NE, Finelli A, et al. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther 2008; 8: 1073-9.
37. Barkin J; CombAT Study Group. Improvements in patient-reported quality of life with dutasteride, tamulosin and the combination: Two year results from the combination of Avodart and tamsulosin (CombAT) trial. Eur Urol Suppl 2008; 7: 95 (Abstract 99).
38. Barkin J, Guimaraes M, Joacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-6.
39. Nickel JC, Barkin J, Koch C, et al. PROACT Investigators. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Ass J 2008; 2: 16-21.
40. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002; (3): CD001423.
41. Boyle P, Robertson C, Lowe F, Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 2004; 93: 751-6.
42. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002; 41: 497-506.
43. Hizli F, Uygur MC. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. Int Urol Nephrol 2007; 39: 879-86.
44. Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 2003; 92: 267-70.
45. Tacklind J, Macdonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2009; (2): CD001423.
46. Edgar AD, Levin R, Constantinou CE, Denis L. A critical review of the pharmacology of the plant extract of Pygeum africanum in the treatment of LUTS. Neurourol Urodyn 2007; 26: 458-63.
47. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002; (1): CD001044.